0001493152-23-025606 Sample Contracts

Unaudited Pro Forma Condensed Consolidated Financial Information

Qualigen Therapeutics, Inc. • July 26th, 2023 • Pharmaceutical preparations

• Company
  Qualigen Therapeutics, Inc.
• Filed
  July 26th, 2023
• Industry
  Pharmaceutical preparations

On July 20, 2023 (the “Closing Date”), Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a stock purchase agreement (the “Purchase Agreement”) with Chembio Diagnostics, Inc. (the “Buyer”), Biosynex, S.A. (“Biosynex”), and Qualigen, Inc., a wholly-owned subsidiary of the Company (the “Subsidiary”). Pursuant to the Purchase Agreement, the Company agreed to sell to the Buyer all of the issued and outstanding shares of common stock (collectively, the “Shares”) of the Subsidiary, which was the legal entity operating the Company’s FastPack™ diagnostics business (the “Transaction”). The Transaction closed on July 20, 2023. Following the consummation of the Transaction, the Subsidiary became a wholly-owned subsidiary of the Buyer.

STOCK PURCHASE AGREEMENT by and among Qualigen Therapeutics, Inc., Chembio Diagnostics, Inc., Biosynex, S.A., and Qualigen, Inc., dated as of July 20, 2023 STOCK PURCHASE AGREEMENT

Stock Purchase Agreement • July 26th, 2023 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • Delaware

• Contract Type
  Stock Purchase Agreement
• Filed
  July 26th, 2023
• Company
  Qualigen Therapeutics, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

This Stock Purchase Agreement (this “Agreement”), dated as of July 20, 2023, is entered into among Qualigen Therapeutics, Inc., a Delaware corporation (“Seller”), Chembio Diagnostics, Inc., a Nevada corporation (“Buyer”), Biosynex, S.A., a French société anonyme (“Guarantor”), and Qualigen, Inc., a Delaware corporation (the “Company”).

AMENDMENT AND SETTLEMENT AGREEMENT

Amendment and Settlement Agreement • July 26th, 2023 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations

• Contract Type
  Amendment and Settlement Agreement
• Filed
  July 26th, 2023
• Company
  Qualigen Therapeutics, Inc.
• Industry
  Pharmaceutical preparations

This Amendment and Settlement Agreement (this “Agreement”) is made with effect as of this 19th day of July 2023, by and between Qualigen Therapeutics, Inc., a Delaware corporation based in California, U.S., (“Qualigen”) and NanoSynex Ltd., a private Israeli company (“Nano”). Each of Qualigen and Nano may be referred to hereinafter as a “Party” and collectively as “Parties”.